Abstract
OnabotulinumtoxinA was introduced to the US market in 2002 as the first botulinum toxin type A (BoNTA) approved for facial aesthetics. This article provides an overview of onabotulinumtoxinA's uses and indications as well as safety and efficacy data. As with other BoNTA products, onabotulinumtoxinA is generally well tolerated. Consideration is also given to clinical applications of the product. Information on handling, storage, and dosing is provided.
Cite
CITATION STYLE
Lorenc, Z. P., Kenkel, J. M., Fagien, S., Hirmand, H., Nestor, M. S., Sclafani, A. P., … Waldorf, H. A. (2013). A review of onabotulinumtoxinA (Botox). Aesthetic Surgery Journal / the American Society for Aesthetic Plastic Surgery. https://doi.org/10.1177/1090820X12474629
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
